Research programme: Ii-Key peptide hybrid vaccines - NuGenerex Immuno-Oncology
Alternative Names: AEH10p; HPV vaccine - NuGenerex Immuno-Oncology; Human papillomavirus vaccine - NuGenerex Immuno-Oncology; Ii-Key/GAD; Ii-Key/HPV16 E7; Ii-Key/insulin; Ii-Key/MHCLatest Information Update: 22 Feb 2023
At a glance
- Originator Antigen Express
- Developer Antigen Express; NuGenerex Immuno-Oncology
- Class Cancer vaccines; Diagnostic agents; Viral vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV infections; Human papillomavirus infections; Hypersensitivity; Influenza virus infections; Smallpox; Type 1 diabetes mellitus
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for HIV infections in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Human papillomavirus infections (Prevention) in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Hypersensitivity (Diagnosis) in USA (unspecified route)